This company listing is no longer active
OTIC Stock Overview
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Otonomy, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.0085 |
| 52 Week High | US$2.54 |
| 52 Week Low | US$0.0075 |
| Beta | 1.53 |
| 1 Month Change | -91.98% |
| 3 Month Change | -91.58% |
| 1 Year Change | -99.62% |
| 3 Year Change | -99.60% |
| 5 Year Change | -99.78% |
| Change since IPO | -99.95% |
Recent News & Updates
Recent updates
Otonomy crashes 73% as mid-stage trial for tinnitus candidate fails
Aug 01Otonomy GAAP EPS of -$0.19 beats by $0.01
Jul 25Otonomy: Hearing Loss And Tinnitus Data In 2022
Apr 04Shareholders Will Probably Hold Off On Increasing Otonomy, Inc.'s (NASDAQ:OTIC) CEO Compensation For The Time Being
Jun 16
Otonomy shares rise after initiating expansion of early-stage OTO-413 hearing loss trial
Jun 15Is Otonomy (NASDAQ:OTIC) Using Debt In A Risky Way?
Feb 02Otonomy And Its Efforts At Resurrecting Itself
Jan 12Are Institutions Heavily Invested In Otonomy, Inc.'s (NASDAQ:OTIC) Shares?
Dec 11Otonomy (OTIC) Investor Presentation - Slideshow
Dec 02Otonomy issues update for Otividex and OTO-313
Nov 30Shareholder Returns
| OTIC | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -92.6% | -1.5% | -3.2% |
| 1Y | -99.6% | 9.7% | 19.3% |
Return vs Industry: OTIC underperformed the US Pharmaceuticals industry which returned -2.3% over the past year.
Return vs Market: OTIC underperformed the US Market which returned -8.9% over the past year.
Price Volatility
| OTIC volatility | |
|---|---|
| OTIC Average Weekly Movement | 27.8% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: OTIC's share price has been volatile over the past 3 months.
Volatility Over Time: OTIC's weekly volatility (28%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 51 | n/a | www.otonomy.com |
Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. It also develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; OTO-825, a gene therapy for the treatment of congenital hearing loss; and OTO-6XX induces hair cell repair and regeneration for the treatment of severe hearing loss.
Otonomy, Inc. Fundamentals Summary
| OTIC fundamental statistics | |
|---|---|
| Market cap | US$582.48k |
| Earnings (TTM) | -US$52.26m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs OTIC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OTIC income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$52.26m |
| Earnings | -US$52.26m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.76 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 75.4% |
How did OTIC perform over the long term?
See historical performance and comparison